RAPS is closely monitoring developments in the Coronavirus (COVID-19) outbreak. See our public safety page for the latest updates.

 
  • French Regulator Charged with Manslaughter for Role in Diabetes Drug Scandal

    • 22 March 2013
    French regulators have announced that judicial authorities have indicted the agency for its role in the regulation of the anti-diabetes drug Mediator, once manufactured by Servier and since blamed in the deaths of hundreds of French citizens. Background Mediator has been a drug plagued by scandal in recent years. A 2007  review  of the medication by the European Medicines Agency found that the use of the drug was dangerous in patients with high blood levels ...
  • CEO Charged with Manslaughter after Drug's Risks Brought to Light

    • 12 December 2012
    The eponymous head of the French pharmaceutical manufacturing group Servier, Jacques Servier, has been charged by a French court with manslaughter and causing injury in a case related to the company's now-discredited diabetes drug Mediator, reports The New York Times and Reuters . Servier, 90, was charged along with six of the Servier Group's companies over claims that the company knowingly and improperly marketed Mediator (benefluorex) without adequately disc...
  • UK NICE Gives Green Light to Servier's Procoralan for Chronic Heart Failure

    The UK's National Institute for Health and Clinical Excellence (NICE) on 7 August issued draft guidance recommending French drugmaker Servier Laboratories' cardiovascular drug Procoralan (ivabradine) be used by the National Health Service (NHS). In clinical trials, ivabradine has been shown to reduce mortality and improve quality of life in patients with certain forms of chronic heart failure. The draft guidance recommends ivabradine as an option for the treatment...
  • European Trade Regulators Charge Companies for 'Pay-for-Delay' Agreements

    • 26 July 2012
    If industry practitioners of so-called pay-for-delay settlements are worried about the climate for the legal agreements in the US after a recent court ruling against the measures, they should be just as concerned about European regulators, reports Reuters and The Financial Times . The agreements are commonly used by pharmaceutical manufacturers of branded products to delay the entry of generic competition in return for large cash payments or other forms of compensat...
  • Reuters: French Regulatory Authority, Executives Searched In Mediator Probe

    • 03 February 2012
    The offices of French regulatory authority Afssaps were searched by French investigators on 2 February as part of an investigation in to deaths associated with Servier's anti-diabetes drug Mediator, according to Reuters . Mediator has been blamed for over 500 deaths in France, and was on the market for more than 30 years. After its introduction to the market in 1976, it was prescribed to nearly 5 million French citizens before it was recalled from the market in late 200...